menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). 

Facebook Comments

Recommended
Details
Comments
  • Overview

    Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). 

Facebook Comments

Schedule24 Jun 2024